Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer
A higher IL-6 concentration was associated with reduced metabolic activity of osimertinib, leading to increased osimertinib exposure. As the IL-6 concentration was higher in NSCLC patients with the IL-6 rs1800796G allele, it might be an independent prognostic factor for patients treated with osimertinib.
Authors
- S. Sakamoto (ORCID: https://orcid.org/0000-0002-3394-2825)
- Masahide Takeda (ORCID: https://orcid.org/0000-0002-7028-7073)
- Yumiko Akamine (ORCID: https://orcid.org/0000-0002-1346-757X)
- Hayato Yokota (ORCID: https://orcid.org/0000-0003-1389-435X)
- Yūji Okuda (ORCID: https://orcid.org/0000-0002-7431-7057)
- Katsutoshi Nakayama
- Masatomo Miura (ORCID: https://orcid.org/0000-0001-7120-2425)
- Kazuhiro Sato (ORCID: https://orcid.org/0000-0003-4758-7868)
Institutions
- Akita University (JP)
- Akita University Hospital (JP)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1007/s00280-025-04772-x
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Japan Society for the Promotion of Science